Standigm Secures Strategic Investment from SK Chemicals for Expanding its AI-Drug Development Capacity


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Pharma News update : Strategic Investments

Standigm Inc. (“Standigm”), a leading workflow artificial intelligence (AI) drug discovery company, and SK Chemicals Co., Ltd (“SK Chemicals”), life science and green chemicals company, announced today that they have signed a strategic partnership contract for collaboration regarding the clinical development of Standigm’s AI-driven drug candidate for non-alcoholic steatohepatitis (“NASH”) and the foundation of Standigm’s Synthesis Research Center within the headquarters of SK Chemicals. This partnership was made in conjunction with SK Chemicals’ participation in Standigm’s pre-IPO round of fundraising.

Under the contract, SK Chemicals will collaborate with Standigm on the clinical development of the NASH drug candidate discovered by Standigm Insight, an AI-aided drug-repurposing platform, which is expected to enter the clinical stage next year. Moreover, Standigm plans to open its Synthesis Research Center in the headquarters of SK Chemicals next month. Standigm will be able to synthesize its AI-driven drug candidates directly and efficiently.

"We are pleased that Standigm’s AI-driven drug candidate has found an experienced partner to bring it to successful clinical development," said Jinhan Kim, co-founder and CEO of Standigm, adding, "This partnership will help us to commercialize our AI-driven drug candidates and enhance our ability and expertise in drug development.”

"Since 2019, we have had open innovation collaboration with Standigm, through which we have already experienced Standigm’s advanced technology. Our co-development effort resulted in the patent filing of a repurposed FDA-approved drug for rheumatoid arthritis (RA) last January”, said Jeonghoon Kim, head of SK Chemicals research center, adding, “This positive experience convinced us that we could create greater synergy by making strategic investment into Standigm.”

Tags : #Standigm #StrategicInvestment #SKChemichals #LatestPharmaNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026